USPTO serial 87623162
PROVIDING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY
Reviewed by CopyMark Law Group
Reg. 5517469Status 710
- Filing date
- Status date
- Registration date
- Jul 17, 2018
- Examiner
- MARSH, BRANDON N
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with PROVIDING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Oxfordshire, GB
Oxfordshire, GB
Oxfordshire, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Melanie Howard
MELANIE HOWARD LOEB & LOEB LLP10100 SANTA MONICA BLVD., SUITE 2200LOS ANGELES, CA 90067UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; biological preparations in the nature of viruses for the treatment of cancer; biological preparations in the nature of viruses for inducing immune response; pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceutical preparations for inducing immune response; vaccines; immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders | SECTION 8 - CANCELLED | — |
| 042 | Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services relating to the aforesaid | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Replimune Limited
- Other trademarks owned by Replimune Limited
- Other trademarks owned by Replimune Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named PROVIDING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 4, 2025 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jul 17, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jul 17, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 1, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 1, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 11, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 29, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 20, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 20, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 14, 2018 | ALIE | ASSIGNED TO LIE | — |
| Mar 1, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 3, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 3, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 3, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 3, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 30, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 29, 2017 | NWAP | NEW APPLICATION ENTERED | — |